

James M Leiper

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9410586/james-m-leiper-publications-by-year.pdf>
Version: 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77 papers	5,683 citations	35 h-index	75 g-index
80 ext. papers	6,118 ext. citations	9.9 avg, IF	5.42 L-index

#	Paper	IF	Citations
77	Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 1490-1504	1.9	3
76	LPS-Induced Hypotension in Pregnancy: The Effect of Progesterone Supplementation. <i>Shock</i> , 2020 , 53, 199-207	3.4	2
75	Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Improves the Outcome of Sepsis in Pregnant Mice. <i>Shock</i> , 2020 , 54, 498-506	3.4	3
74	ADMA: A Key Player in the Relationship between Vascular Dysfunction and Inflammation in Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
73	The role of alanine glyoxylate transaminase-2 (agxt2) in alanine and carnosine metabolism of healthy mice and humans. <i>European Journal of Applied Physiology</i> , 2020 , 120, 2749-2759	3.4	0
72	Rapid onset of severe septic shock in the pregnant mouse. <i>Biology of Reproduction</i> , 2019 , 100, 505-513	3.9	5
71	Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase 1. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, F74-F78	4.3	3
70	NRF2 prevents hypertension, increased ADMA, microvascular oxidative stress, and dysfunction in mice with two weeks of ANG II infusion. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2018 , 314, R399-R406	3.2	17
69	Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity. <i>Critical Care</i> , 2018 , 22, 336	10.8	4
68	The response of the innate immune and cardiovascular systems to LPS in pregnant and nonpregnant mice. <i>Biology of Reproduction</i> , 2017 , 97, 258-272	3.9	13
67	Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways. <i>PLoS ONE</i> , 2017 , 12, e0183025	3.7	8
66	Sepsis 2016 Paris. <i>Critical Care</i> , 2016 , 20,	10.8	78
65	Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis. <i>Experimental Eye Research</i> , 2016 , 147, 148-155	3.7	12
64	A Novel Pathway for Metabolism of the Cardiovascular Risk Factor Homoarginine by alanine:glyoxylate aminotransferase 2. <i>Scientific Reports</i> , 2016 , 6, 35277	4.9	19
63	Endothelial Dimethylarginine Dimethylaminohydrolase 1 Is an Important Regulator of Angiogenesis but Does Not Regulate Vascular Reactivity or Hemodynamic Homeostasis. <i>Circulation</i> , 2015 , 131, 2217-25	16.7	26
62	Dimethylarginine dimethylaminohydrolase 2 regulates nitric oxide synthesis and hemodynamics and determines outcome in polymicrobial sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1382-92	9.4	29
61	Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 3045-59	12.7	25

60	Reply to letter regarding article, "evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs". <i>Circulation</i> , 2015 , 132, e213-4	16.7	2
59	Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. <i>Circulation</i> , 2015 , 131, 633-42	16.7	60
58	Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity. <i>Pain</i> , 2015 , 156, 2052-2060	8	8
57	Response to letters regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine". <i>Circulation</i> , 2014 , 129, e428	16.7	6
56	Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. <i>Lancet, The</i> , 2014 , 384, 504-13	40	109
55	miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. <i>Biochemical Journal</i> , 2014 , 462, 103-12	3.8	41
54	Overexpression of GTP cyclohydrolase 1 feedback regulatory protein is protective in a murine model of septic shock. <i>Shock</i> , 2014 , 42, 432-9	3.4	7
53	Pharmacological inhibition of DDAH1 improves survival, haemodynamics and organ function in experimental septic shock. <i>Biochemical Journal</i> , 2014 , 460, 309-16	3.8	23
52	Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. <i>Pulmonary Circulation</i> , 2013 , 3, 675-91	2.7	15
51	Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. <i>Circulation</i> , 2013 , 128, 845-53	16.7	160
50	The role of ADMA in the regulation of pulmonary endothelial cell-to-cell communication, endothelial permeability and angiogenesis. <i>Vascular Pharmacology</i> , 2012 , 56, 333-334	5.9	
49	Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2892-900	9.4	60
48	The role of ATM in response to metformin treatment and activation of AMPK. <i>Nature Genetics</i> , 2012 , 44, 360-1	36.3	28
47	Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 1343-53	9.4	75
46	Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2589-97	9.4	26
45	The Therapeutic Potential of Dimethylarginine Dimethylaminohydrolase-Mediated Regulation of Nitric Oxide Synthesis 2012 , 61-88		
44	The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 277-91	64.1	118
43	Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. <i>Journal of Pathology</i> , 2011 , 225, 344-52	9.4	25

42	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. <i>Circulation</i> , 2011 , 123, 1194-204	16.7	34
41	The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. <i>Science Translational Medicine</i> , 2011 , 3, 87ra53	17.5	50
40	A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development. <i>International Journal of Developmental Biology</i> , 2010 , 54, 215-20	1.9	18
39	Adenoviral-mediated overexpression of DDAH improves vascular tone regulation. <i>Vascular Medicine</i> , 2010 , 15, 205-13	3.3	21
38	Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H251-8	5.2	37
37	Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. <i>Kidney International</i> , 2010 , 77, 459-67	9.9	22
36	Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. <i>Acta Histochemica</i> , 2010 , 112, 413-23	2	15
35	Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. <i>Molecular Biology of the Cell</i> , 2009 , 20, 33-42	3.5	50
34	The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 2117-24	9.4	46
33	Over-expression of GTP-cyclohydrolase 1 feedback regulatory protein attenuates LPS and cytokine-stimulated nitric oxide production. <i>Vascular Medicine</i> , 2008 , 13, 29-36	3.3	14
32	Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. <i>Diabetes</i> , 2008 , 57, 172-80	0.9	80
31	Rho GTPases and hypoxia in pulmonary vascular endothelial cells. <i>Methods in Enzymology</i> , 2008 , 439, 267-83	1.7	10
30	Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. <i>Hepatology</i> , 2007 , 45, 62-71	11.2	87
29	Discovery of inhibitors of the penten superfamily protein dimethylarginine dimethylaminohydrolase (DDAH), by virtual screening and hit analysis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 3953-6	2.9	23
28	Disruption of methylarginine metabolism impairs vascular homeostasis. <i>Nature Medicine</i> , 2007 , 13, 198-203	20.5	327
27	Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. <i>Circulation Research</i> , 2007 , 101, 627-35	15.7	108
26	Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 292, L18-24	5.8	101
25	The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. <i>Journal of Cell Science</i> , 2007 , 120, 929-42	5.3	79

24	The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. <i>Journal of Cell Science</i> , 2007 , 120, 1502-1502	5.3	
23	The synthesis and metabolism of asymmetric dimethylarginine (ADMA). <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 33-38	2.8	73
22	New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1419-20	9.4	10
21	Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation. <i>Pediatric Research</i> , 2006 , 59, 767-72	3.2	15
20	Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 4670-8	8.3	44
19	The DDAH-ADMA-NOS pathway. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 744-6	3.2	29
18	Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. <i>PLoS Medicine</i> , 2005 , 2, e264	11.6	42
17	Endogenous production of nitric oxide synthase inhibitors. <i>Vascular Medicine</i> , 2005 , 10, S3-S9	3.3	33
16	Endogenous production of nitric oxide synthase inhibitors. <i>Vascular Medicine</i> , 2005 , 10 Suppl 1, S3-9	3.3	29
15	Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 1023-30	9.4	441
14	Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 1455-9	9.4	471
13	The DDAH/ADMA/NOS pathway. <i>Atherosclerosis Supplements</i> , 2003 , 4, 33-40	1.7	226
12	Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 308, 984-9	3.4	65
11	Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. <i>Circulation</i> , 2003 , 108, 1493-8	16.7	108
10	Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. <i>Circulation</i> , 2003 , 107, 1195-201	16.7	114
9	Blocking NO synthesis: how, where and why?. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 939-50	64.1	266
8	S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 13527-32	11.5	257
7	all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. <i>Circulation Research</i> , 2002 , 90, 764-9	15.7	110

6	Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. <i>Nature Structural Biology</i> , 2001 , 8, 679-83		176
5	Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. <i>Genomics</i> , 2000 , 68, 101-5	4.3	159
4	Identification of microbial dimethylarginine dimethylaminohydrolase enzymes. <i>Molecular Microbiology</i> , 1999 , 33, 1278-9	4.1	18
3	Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. <i>Cardiovascular Research</i> , 1999 , 43, 542-8	9.9	343
2	Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. <i>Biochemical Journal</i> , 1999 , 343, 209-214 ^{3.8}		395
1	Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. <i>Biochemical Journal</i> , 1999 , 343, 209	3.8	109